Boehringer Ingelheim (BI) and Gubra, a provider of contract services for drug discovery and development, have entered into a collaboration and license agreement for the development of poly-agonist peptides to treat obesity. This new research and development program is in addition to an ongoing collaboration between BI and Gubra in the obesity field that was launched in 2017.

Under the agreement, Gubra may receive up to EUR 240 million ($269.4 million) in upfront and success-based development and commercialization milestones, in addition to double-digit royalties on global net sales.

The new collaboration is to develop anti-obesity peptide poly-agonists. Gubra has expertise in the design, synthesis, pharmaceutical characterization, and in vivo testing of therapeutic peptides, and BI has expertise in the research and development of medicines in cardiometabolic diseases. BI has multiple products for thromboembolic diseases, Type 2 diabetes, acute stroke and myocardial infarction, hypertension and cardiovascular death risk reduction. Gubra is a privately held biotech company headquartered in Hørsholm, Denmark and offers counselling and contract research services focusing on obesity, diabetes, nonalcoholic steatohepatitis, and diabetic complications.

Source: Boehringer Ingelheim